Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 10 (October)

1. Treatment options for chronic hepatitis B and C infection in children.
   Expert Rev Anti Infect Ther, 4(4): 583-91. [Abstract] [Full-text]
2. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.
   Expert Rev Anti Infect Ther, 4(4): 549-61. [Abstract] [Full-text]
3. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada.
   BMC Public Health, 6: 229. [Abstract] [Full-text]
4. Circulating viral core and E1 antigen levels as supplemental markers for HCV chronic hepatitis.
   Virol J, 3: 67. [Abstract] [Full-text]
5. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma.
   Cancer, 107(7): 1562-9. [Abstract] [Full-text]
6. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis.
   Eur J Cancer, 42(15): 2524-9. [Abstract] [Full-text]
7. Involvement of endoplasmic reticulum in hepatitis B virus replication.
   Virus Res, 121(2): 116-21. [Abstract] [Full-text]
8. Mitochondrial dysfunction in hepatitis C virus infection.
   Biochim Biophys Acta, 1757(9): 1429-37. [Abstract] [Full-text]
9. Mutations of the Hepatitis C virus protein NS4B on either side of the ER membrane affect the efficiency of subgenomic replicons.
   Virus Res, 121(2): 169-78. [Abstract] [Full-text]
10. HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression.
    Virus Res, 121(2): 134-43. [Abstract] [Full-text]
11. Life saving cyclophosphamide treatment in a girl with giant cell hepatitis and autoimmune haemolytic anaemia: case report and up-to-date on therapeutical options.
    Dig Liver Dis, 38(11): 846-50. [Abstract] [Full-text]
12. Acute alcoholic hepatitis.
    J Clin Gastroenterol, 40(9): 833-41. [Abstract] [Full-text]
13. Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination.
    Pediatrics, 118(4): 1403-8. [Abstract] [Full-text]
14. Antioxidant effects and hepatoprotective activity of 2,5-dihydroxy-4,3'-di(beta-d-glucopyranosyloxy)-trans-stilbene from Morus bombycis Koidzumi roots on CCl4-induced liver damage.
    Free Radic Res, 40(9): 986-92. [Abstract] [Full-text]
15. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice.
    Hepatology, 44(4): 936-44. [Abstract] [Full-text]
16. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection.
    Hepatology, 44(4): 925-35. [Abstract] [Full-text]
17. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.
    Hepatology, 44(4): 915-24. [Abstract] [Full-text]
18. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV.
    Hepatology, 44(4): 907-14. [Abstract] [Full-text]
19. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes.
    Hepatology, 44(4): 896-906. [Abstract] [Full-text]
20. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.
    Hepatology, 44(4): 945-54. [Abstract] [Full-text]
21. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo.
    J Exp Med, 203(10): 2329-38. [Abstract] [Full-text]
22. Mesocaval stenting for therapy of portal hypertension after orthotopic liver transplantation.
    Transpl Int, 19(11): 937-40. [Abstract] [Full-text]
23. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.
    Liver Transpl, 12(10): 1496-503. [Abstract] [Full-text]
24. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Liver Transpl, 12(10): 1489-95. [Abstract] [Full-text]
25. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.
    J Hepatol, 45(5): 646-53. [Abstract] [Full-text]
26. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.
    J Clin Microbiol, 44(10): 3600-7. [Abstract] [Full-text]
27. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.
    J Clin Microbiol, 44(10): 3562-8. [Abstract] [Full-text]
28. Antiviral treatment of hepatitis C.
    Expert Opin Pharmacother, 7(15): 2025-35. [Abstract] [Full-text]
29. Redox modulation of the hepatitis C virus replication complex is calcium dependent.
    Free Radic Biol Med, 41(9): 1488-98. [Abstract] [Full-text]
30. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients.
    Clin Infect Dis, 43(9): 1209-12. [Abstract] [Full-text]
31. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.
    Clin Infect Dis, 43(9): 1154-9. [Abstract] [Full-text]
32. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
    Intervirology, 49(6): 362-9. [Abstract] [Full-text]
33. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Intervirology, 49(6): 352-61. [Abstract] [Full-text]
34. Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B.
    Intervirology, 49(6): 339-45. [Abstract] [Full-text]
35. Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinomas from chronic hepatitis C and liver cirrhosis.
    Intervirology, 49(6): 327-38. [Abstract] [Full-text]
36. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Intervirology, 49(6): 319-26. [Abstract] [Full-text]
37. Susceptibility of healthcare workers in Kenya to hepatitis B: new strategies for facilitating vaccination uptake.
    J Hosp Infect, 64(3): 271-7. [Abstract] [Full-text]
38. Enterohepatic Helicobacter species isolated from the ileum, liver and colon of a baboon with pancreatic islet amyloidosis.
    J Med Microbiol, 55: 1591-5. [Abstract] [Full-text]
39. Cap-dependent and hepatitis C virus internal ribosome entry site-mediated translation are modulated by phosphorylation of eIF2alpha under oxidative stress.
    J Gen Virol, 87: 3251-62. [Abstract] [Full-text]
40. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection.
    J Gen Virol, 87: 3225-32. [Abstract] [Full-text]
41. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
    Gastroenterology, 131(4): 1253-61. [Abstract] [Full-text]
42. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Gastroenterology, 131(4): 1040-8. [Abstract] [Full-text]
43. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
    Gastroenterology, 131(4): 997-1002. [Abstract] [Full-text]
44. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
    Microbes Infect, 8(9): 2432-41. [Abstract] [Full-text]
45. Protective effect of Lygodium flexuosum (L.) Sw. (Lygodiaceae) against D-galactosamine induced liver injury in rats.
    J Ethnopharmacol, 108(1): 116-23. [Abstract] [Full-text]
46. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?
    Infection, 34(5): 282-4. [Abstract] [Full-text]
47. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.
    J Pediatr Gastroenterol Nutr, 43(4): 499-505. [Abstract] [Full-text]
48. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.
    J Pediatr Gastroenterol Nutr, 43(4): 494-8. [Abstract] [Full-text]
49. Imatinib mesylate-induced acute hepatitis with autoimmune features.
    Eur J Gastroenterol Hepatol, 18(11): 1235-7. [Abstract] [Full-text]
50. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy.
    Eur J Gastroenterol Hepatol, 18(11): 1227-31. [Abstract] [Full-text]
51. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Liver Int, 26(9): 1148-54. [Abstract] [Full-text]
52. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Liver Int, 26(9): 1119-25. [Abstract] [Full-text]
53. Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C.
    Liver Int, 26(9): 1100-10. [Abstract] [Full-text]
54. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection.
    Liver Int, 26(9): 1095-9. [Abstract] [Full-text]
55. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases.
    Liver Int, 26(9): 1087-94. [Abstract] [Full-text]
56. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Liver Int, 26(9): 1079-86. [Abstract] [Full-text]
57. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
    Am J Gastroenterol, 101(10): 2360-78. [Abstract] [Full-text]
58. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
    Am J Gastroenterol, 101(10): 2275-82. [Abstract] [Full-text]
59. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
    Am J Gastroenterol, 101(10): 2269-74. [Abstract] [Full-text]
60. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.
    Am J Gastroenterol, 101(10): 2254-62. [Abstract] [Full-text]
61. Higher prevalence and severity of hepatic encephalopathy in patients with HCV cirrhosis and diabetes mellitus: is presence of autonomic neuropathy the missing part of the puzzle?
    Am J Gastroenterol, 101(10): 2244-6. [Abstract] [Full-text]
62. Genetic polymorphism of interferon-gamma, interferon-gamma receptor, and interferon regulatory factor-1 genes in patients with hepatitis B virus infection.
    Biochem Genet, 44(5): 246-55. [Abstract] [Full-text]
63. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Clin Exp Immunol, 146(2): 270-7. [Abstract] [Full-text]
64. Quantitative measurement of hepatitis C virus core antigen is affected by the presence of cryoglobulins.
    Clin Exp Immunol, 146(2): 211-7. [Abstract] [Full-text]
65. Discovery of significant variants containing large deletions in the 5'UTR of human hepatitis C virus (HCV).
    Virol J, 3: 82. [Abstract] [Full-text]
66. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
    Transplantation, 82(7): 853-6. [Abstract] [Full-text]
67. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    J Gastroenterol, 41(9): 862-72. [Abstract] [Full-text]
68. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.
    JAMA, 296(15): 1843-50. [Abstract] [Full-text]
69. Isoniazid-induced hepatotoxicity in rat hepatocytes of gel entrapment culture.
    Toxicol Lett, 167(1): 66-74. [Abstract] [Full-text]
70. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity.
    J Autoimmun, 27(2): 134-9. [Abstract] [Full-text]
71. Evaluation of the clinical performance of the Beckman Coulter Access AbHBsII immunoassay for the detection of hepatitis B surface antibodies.
    J Clin Virol, 37(3): 213-7. [Abstract] [Full-text]
72. Dynamic changes of heme oxygenase-1 and carbon monoxide production in acute liver injury induced by carbon tetrachloride in rats.
    Toxicology, 228(1): 51-7. [Abstract] [Full-text]
73. Simplified PCR protocols for INNO-LiPA HBV Genotyping and INNO-LiPA HBV PreCore assays.
    J Clin Virol, 37(3): 218-21. [Abstract] [Full-text]
74. Outcomes and treatment of acute hepatitis C virus infection in a United States population.
    Clin Gastroenterol Hepatol, 4(10): 1278-82. [Abstract] [Full-text]
75. A promoter polymorphism in the interferon alpha-2 gene is associated with the clinical presentation of hepatitis B.
    Mutat Res, 601(1): 137-43. [Abstract] [Full-text]
76. Antioxidant activity of the oyster mushroom, Pleurotus ostreatus, on CCl(4)-induced liver injury in rats.
    Food Chem Toxicol, 44(12): 1989-96. [Abstract] [Full-text]
77. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D.
    Clin Gastroenterol Hepatol, 4(10): 1271-7. [Abstract] [Full-text]
78. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B.
    J Clin Virol, 37(3): 206-12. [Abstract] [Full-text]
79. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002.
    Eur J Epidemiol, 21(7): 545-9. [Abstract] [Full-text]
80. Significance of low or normal serum gamma glutamyl transferase level in infants with idiopathic neonatal hepatitis.
    Eur J Pediatr, 165(11): 795-801. [Abstract] [Full-text]
81. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Gut, 55(11): 1631-8. [Abstract] [Full-text]
82. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment.
    Gut, 55(11): 1624-30. [Abstract] [Full-text]
83. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient.
    J Infect, 53(5): e215-8. [Abstract] [Full-text]
84. Hepatitis B vaccination status among healthy adults in Germany.
    Health Policy, 79(2): 306-12. [Abstract] [Full-text]
85. New nucleic acid diagnostic tests in viral hepatitis.
    Semin Liver Dis, 26(4): 309-17. [Abstract] [Full-text]
86. Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis.
    J Clin Exp Neuropsychol, 28(8): 1346-61. [Abstract] [Full-text]
87. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation.
    Am J Transplant, 6(11): 2680-5. [Abstract] [Full-text]
88. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C.
    Am J Transplant, 6(11): 2812-6. [Abstract] [Full-text]
89. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
90. Bicyclol for chronic hepatitis B.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
91. Antituberculosis drugs and hepatotoxicity.
    Respirology, 11(6): 699-707. [Abstract] [Full-text]
92. Treatment rates in patients with chronic hepatitis C after liver biopsy.
    J Viral Hepat, 13(11): 783-6. [Abstract] [Full-text]
93. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection.
    J Viral Hepat, 13(11): 775-82. [Abstract] [Full-text]
94. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
    J Viral Hepat, 13(11): 770-4. [Abstract] [Full-text]
95. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
    J Viral Hepat, 13(11): 762-9. [Abstract] [Full-text]
96. Detection of a 5' end subgenome of hepatitis C virus terminating at nucleotide 384 in patients' plasma and liver tissues.
    J Viral Hepat, 13(11): 746-55. [Abstract] [Full-text]
97. Type-IV Indian swine HEV infects rhesus monkeys.
    J Viral Hepat, 13(11): 742-5. [Abstract] [Full-text]
98. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.
    J Viral Hepat, 13(11): 734-41. [Abstract] [Full-text]
99. B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels.
    J Viral Hepat, 13(11): 725-33. [Abstract] [Full-text]
100. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase.
     J Viral Hepat, 13(11): 715-24. [Abstract] [Full-text]
101. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus.
     AIDS Patient Care STDS, 20(10): 678-92. [Abstract] [Full-text]
102. An artificial neural network approach to the drug efficacy of interferon treatments.
     Pharmacogenomics, 7(7): 1017-24. [Abstract] [Full-text]
103. Toxicogenomics strategies for predicting drug toxicity.
     Pharmacogenomics, 7(7): 1003-16. [Abstract] [Full-text]
104. The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice.
     Eur J Pharmacol, 550(1): 39-46. [Abstract] [Full-text]
105. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
     J Antimicrob Chemother, 58(5): 1031-5. [Abstract] [Full-text]
106. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.
     Cancer, 107(8): 1852-8. [Abstract] [Full-text]
107. Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study.
     Clin Exp Med, 6(3): 124-8. [Abstract] [Full-text]
108. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma.
     Ann Surg, 244(5): 771-80. [Abstract] [Full-text]
109. Hepatitis C virus infection and neurocognitive function.
     Neurology, 67(8): 1482-5. [Abstract] [Full-text]
110. The association of chronic hepatitis B and myopathy.
     Neurology, 67(8): 1467-9. [Abstract] [Full-text]
111. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women.
     Obes Surg, 16(10): 1351-8. [Abstract] [Full-text]
112. Recommendations and potential future options in the treatment of hepatitis B.
     Expert Opin Pharmacother, 7(16): 2225-31. [Abstract] [Full-text]
113. Histologic findings in recurrent HBV.
     Liver Transpl, 12(11): S50-3. [Abstract] [Full-text]
114. Acute rejection in HCV-infected liver transplant recipients: The great conundrum.
     Liver Transpl, 12(11): S38-47. [Abstract] [Full-text]
115. Early recurrence of hepatitis C virus infection after liver transplantation.
     Liver Transpl, 12(11): S32-7. [Abstract] [Full-text]
116. Hepatitis B in liver transplant recipients.
     Liver Transpl, 12(11): S54-64. [Abstract] [Full-text]
117. Hydranencephaly with cholestasis and giant hepatitis.
     J Clin Gastroenterol, 40(10): 956-8. [Abstract] [Full-text]
118. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies.
     JAMA, 296(16): 2005-11. [Abstract] [Full-text]
119. Dynamics of hepatic enzyme activity following birth asphyxia.
     Acta Paediatr, 95(11): 1405-11. [Abstract] [Full-text]
120. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
     Clin Ther, 28(9): 1327-34. [Abstract] [Full-text]
121. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
     J Eur Acad Dermatol Venereol, 20(10): 1201-6. [Abstract] [Full-text]
122. Hepatitis A surveillance in England--how many cases are not reported and does it really matter?
     Epidemiol Infect, 134(6): 1299-302. [Abstract] [Full-text]
123. Outbreak of hepatitis A in two federal states of Germany: bakery products as vehicle of infection.
     Epidemiol Infect, 134(6): 1292-8. [Abstract] [Full-text]
124. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.
     Diabetes Care, 29(11): 2462-6. [Abstract] [Full-text]
125. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.
     Hepatology, 44(5): 1098-109. [Abstract] [Full-text]
126. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
     Hepatology, 44(5): 1146-57. [Abstract] [Full-text]
127. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
     Hepatology, 44(5): 1086-97. [Abstract] [Full-text]
128. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
     Hepatology, 44(5): 1110-6. [Abstract] [Full-text]
129. Hepatitis C virus reinfection in injection drug users.
     Hepatology, 44(5): 1139-45. [Abstract] [Full-text]
130. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C.
     Hepatology, 44(5): 1122-38. [Abstract] [Full-text]
131. Antioxidative and in vitro hepatoprotective activity of Bupleurum kaoi leaf infusion.
     Phytother Res, 20(11): 1003-8. [Abstract] [Full-text]
132. Protective effects of Zingiber officinale (Zingiberaceae) against carbon tetrachloride and acetaminophen-induced hepatotoxicity in rats.
     Phytother Res, 20(11): 997-1002. [Abstract] [Full-text]
133. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.
     J Virol, 80(22): 11094-104. [Abstract] [Full-text]
134. Cellular immune responses associated with occult hepatitis C virus infection of the liver.
     J Virol, 80(22): 10972-9. [Abstract] [Full-text]
135. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.
     Am J Med, 119(11): 977-85. [Abstract] [Full-text]
136. Hepatitis A in Tunisia: phylogenetic analysis of hepatitis A virus from 2001 to 2004.
     J Virol Methods, 138(1): 109-16. [Abstract] [Full-text]
137. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
     Int J Infect Dis, 10(6): 453-7. [Abstract] [Full-text]
138. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients.
     J Virol Methods, 138(1): 70-9. [Abstract] [Full-text]
139. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.
     J Virol, 80(22): 11398-403. [Abstract] [Full-text]
140. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.
     J Virol Methods, 138(1): 30-9. [Abstract] [Full-text]
141. New therapeutic options for hepatitis C.
     Curr Opin Infect Dis, 19(6): 615-22. [Abstract] [Full-text]
142. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse.
     J Clin Oncol, 24(31): 5005-9. [Abstract] [Full-text]
143. Postinfantile giant-cell hepatitis associated with ulcerative colitis and autoimmune hepatitis.
     J Gastroenterol Hepatol, 21(12): 1863-4. [Abstract] [Full-text]
144. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane.
     J Gastroenterol Hepatol, 21(12): 1821-5. [Abstract] [Full-text]
145. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.
     J Gastroenterol Hepatol, 21(12): 1789-93. [Abstract] [Full-text]
146. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
     J Gastroenterol Hepatol, 21(12): 1783-8. [Abstract] [Full-text]
147. Identification of the first strain of swine hepatitis E virus in South America and prevalence of anti-HEV antibodies in swine in Argentina.
     J Med Virol, 78(12): 1579-83. [Abstract] [Full-text]
148. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
     J Med Virol, 78(12): 1560-3. [Abstract] [Full-text]
149. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia.
     J Med Virol, 78(12): 1554-9. [Abstract] [Full-text]
150. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses.
     J Med Virol, 78(12): 1688-95. [Abstract] [Full-text]
151. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain.
     J Med Virol, 78(12): 1599-608. [Abstract] [Full-text]
152. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection.
     J Med Virol, 78(12): 1572-8. [Abstract] [Full-text]
153. Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea.
     J Med Virol, 78(12): 1564-71. [Abstract] [Full-text]
154. Prevalence of hepatitis A virus infection among municipal solid-waste workers.
     Int J Clin Pract, 60(11): 1432-6. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.